Idelvion manufacturer?

Idelvion Manufacturer: Shire plc (Now Part of Takeda)

Idelvion is a long-lasting clotting factor VIII treatment for hemophilia A. It is manufactured by Shire plc, which is now a part of Takeda Pharmaceutical Company. Takeda obtained the rights to Idelvion through its acquisition of Shire in 2020.

Origin and Development

Idelvion was initially developed by BioLife Plasma Services and developed by CSL Behring.[1] However, the rights to Idelvion were later acquired by Shire,[2] which was involved in its marketing and distribution.

Current Status and Availability

After Takeda's acquisition of Shire, Takeda continues to market and distribute Idelvion worldwide. The treatment is available in several countries, including the United States, Canada, and parts of Europe.

Regulatory Approvals and Patents

Idelvion has received approval from regulatory agencies such as the US FDA and the European Medicines Agency (EMA).[3] However, it also has patents that may affect its availability and pricing. According to DrugPatentWatch.com, Idelvion's patents are set to expire in the mid-2020s, which may impact its exclusivity and pricing in the future.[4]

References

[1] CSL Behring. (n.d.). Idelvion. Retrieved from https://www.cslbehring.com/information-portal/our-products-and-solutions/idelvion

[2] Shire plc. (n.d.). Idelvion. Retrieved from https://www.shire.com/our-products/patient-solutions-and-treatments/hemophilia/idelvion

[3] Takeda Pharmaceutical Company. (n.d.). Idelvion. Retrieved from https://www.takeda.com/product/idelvion/

[4] DrugPatentWatch.com. (n.d.). Idelvion. Retrieved from https://www.drugpatentwatch.com/DrugPatent/DEA-2020-007-001

Sources

1. [1] CSL Behring. (n.d.). Idelvion.
2. [2] Shire plc. (n.d.). Idelvion.
3. [3] Takeda Pharmaceutical Company. (n.d.). Idelvion.
4. [4] DrugPatentWatch.com. (n.d.). Idelvion.